http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
항사구체기저막 항체 및 MPO-ANCA 양성인 초승달 사구체신염
조종태 ( Jong Tae Cho ),고재향 ( Jai Hyang Go ),정경연 ( Kyong Yeun Jung ) 대한내과학회 2012 대한내과학회지 Vol.83 No.5
Rapidly progressive glomerulonephritis (RPGN) is a clinical syndrome involving abrupt or insidious onset of hematuria, proteinuria, and anemia, and rapidly progressive renal failure. Crescentic glomerulonephritis is a histopathological term for RPGN showing extensive extracapillary proliferation, i.e., crescent formation. There are three major immunopathological categories of crescentic glomerulonephritis: anti-glomerular basement membrane (anti-GBM) antibody disease, immune complex-mediated, and pauci-immune (anti-neutrophil cytoplasmic autoantibody [ANCA]-positive). A small minority of all patients with glomerulonephritis develop crescentic glomerulonephritis. Anti-GBM antibodies and ANCA rarely coexist. There have been a few reports of dual positive crescentic glomerulonephritis with anti-GBM antibodies and ANCA in Korea. Here, we describe the case of a 73-year-old woman showing RPGN clinically and crescentic glomerulonephritis pathologically with coexisting anti-GBM antibodies and myeloperoxidase-ANCA. (Korean J Med 2012;83:654-658)
막증식성 사구체 신염을 동반한 면역글로불린 G4 연관 신장 질환 1예
조종태 ( Jong Tae Cho ),이은경 ( Eun-kyoung Lee ),고재향 ( Jai Hyang Go ),이용문 ( Yong-moon Lee ),이화영 ( Hwa Young Lee ),김소미 ( So Mi Kim ) 대한내과학회 2021 대한내과학회지 Vol.96 No.1
본 증례에서는 신기능 저하, 신우의 종괴로 내원하여 혈청학적 검사, 영상의학적 검사를 바탕으로 신장 조직 검사를 통해 간질성 신염 및 막증식성 사구체 신염을 동시에 보인 IgG4 연관 신장 질환을 진단하고, 스테로이드로 치료한 1예를 경험하여 문헌고찰과 함께 보고하는 바이다. Immunoglobulin G4 (IgG4)-related kidney disease is a chronic immune-mediated fibro-inflammatory disorder characterized by multiple organ infiltration with IgG4-positive plasma cells, storiform fibrosis, and obliterative phlebitis or tumefactive lesions. Previous studies have explored IgG4-related kidney disease, increasing our understanding of its clinical manifestations, and pathological and radiologic findings. However, IgG4-related kidney disease can be misdiagnosed since it mimics malignancies. We report a case of a 77-year-old Korean man diagnosed with IgG4-related kidney disease with membranous proliferative glomerulonephritis, presenting with a renal pelvic mass suspected of being malignant. (Korean J Med 2021;96:48-52)
미세변화 신증후군에 합병된 간문맥, 비장정맥 및 장간막정맥 혈전증
조종태(Jong Tae Cho),김지훈(Ji Hoon Kim),박정식(Jung Sik Park),이상구(Sang Koo Lee),김순배(Soon Bae Kim),양현숙(Hyun Suk Yang),조경식(Kyoung Sik Cho) 대한신장학회 2000 Kidney Research and Clinical Practice Vol.19 No.3
An association between nephrotic syndrome and thromboembolic phenomena has been known for many years. Most common sites of venous throm-bosis in nephrotic syndrome are al vein and deep vein of lower extremity. We report a case of minimal change nephrotic syndrome associated with unusual extensive venous thrombosis. A 29-year-old man was transferred to our hospital with severe abdominal pain and ascites. 2 months before admission, he was diagnosed as minimal change nephropathy at another hospital and treated with steroid therapy but he had persistent proteinuria on admission. The ab- dominal ultrasonography and CT scan revealed diffuse thrombosis of left renal vein, splenic vein, su-perior mesenteric vein and portal vein. Deep vein thrombosis of lower extremity was also found but not pulmonary embolism. There was no evidence of other primary hypercoagulable disease. He was treat- ed with intravenous heparin immediately and three days later, abdominal pain disappeared. Prednisolone and cyclophosphamide were administered as well. After 1 month of therapy, proteinuria was resolved. Abdominal CT scan, taken after 2 months of therapy, revealed that diffuse thrombosis were almost re- solved. From this case, diffuse abdominal thrombosis should be included as a diffrential diagnosis in a ne-phrotic patient with abdominal pain.
조종태(Jong Tae Cho),김근호(Geun Ho Kim),엄재호(Jae Ho Earm),안규리(Gu Rie Ahn),한진석(Jin Suk Han),김성권(Suhng Gwon Kim),이정상(Jung Sang Lee) 대한내과학회 1990 대한내과학회지 Vol.39 No.6
N/A We observed the clinical features, underlying disorders, complications, treatment and outcome of 12 cases of distal renal tubular acidosis and the following results were obtained. 1) The patient`s age ranged from 23 to 53 years old (39±9) and female to male ratio was 10:2. 2) The chief complaints on admission were generalized weakness (5), periodic paralysis (4), recurrent renal stone (2) and paresthesia (1). 3) The identified underlying disorders were systemic lupus erythematosus (3), medullary spongy kidney (2), Sjogren`s syndrome (2), and hyperparathyroidism (1). 4) The major complications were nephrolithiasis (3), nephrocalcinosis (3), osteomalacia (2) and rhabdomyolysis (1). 5) Replacement of alkali and potassium, and specific therapy for underlying disorders showed good outcome.
트리테이스프로텍트 <sup>®</sup>정(라미프릴 10mg)에 대한 라미프린 <sup>®</sup>정의 생물학적동등성
오수연,조종태,김형건,김윤균,Oh, Soo-Yeon,Cho, Jong-Tae,Kim, Hyung-Gun,Kim, Yoon-Gyoon 한국약제학회 2008 Journal of Pharmaceutical Investigation Vol.38 No.1
To evaluate the bioequivalence of two ramipril formulations, a standard 2-way randomized cross-over study was conducted in twenty-six healthy male Korean volunteers. A single oral dose of 10 mg of test formulation $Ramiprin^{(R)}$ (tablet) or reference formulation Tritace $Protect^{(R)}$ (tablet) was administered with one-week washout period. Plasma concentrations of ramipril were assayed over a period of 12 hr with a well validated method using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The values of area under the plasma concentration-time curve, from time zero to last sampling time $(AUC_t)$ and from time zero to time infinity $(AUC_{inf})$ were $77.45{\pm}44.78\;and\;78.96{\pm}45.64$ for test, and $70.30{\pm}42.27\;and\;71.99{\pm}43.55ng\;hr/mL$ for reference formulation, respectively. Similarly, maximum concentration $(C_{max})$ and elimination half-life $(t_{1/2})$ were $65.61{\pm}19.96ng/mL$ and $2.15{\pm}0.75hr$ for test, and $63.63{\pm}25.50ng/mL$ and $2.16{\pm}0.73hr$ for reference formulations, respectively. Time to reach maximum concentration $(T_{max})$ for the test and the reference, were $0.51{\pm}0.22hr\;and\;0.52{\pm}0.18hr$, respectively. The parametric 90% confidence intervals on the mean of the differences between the two formulations (test-reference) of the log-transformed values of $AUC_t\;and\;C_{max}$ were 1.03 to 1.19 and 0.98 to 1.17, respectively. The overall results indicate that the two formulations are bioequivalent and can be prescribed interchangeably.
이팩사<sup>®</sup> XR서방캅셀(벤라팍신, 75 mg)에 대한 벤팍신<sup>®</sup>OR서방정의 생물학적동등성
디펜드라 쿠마 아리얼,오수연,조종태,김형건,김윤균,Aryal, Dipendra Kumar,Oh, Soo-Yeon,Cho, Jong-Tae,Kim, Hyung-Gun,Kim, Yoon-Gyoon 한국약제학회 2007 Journal of Pharmaceutical Investigation Vol.37 No.6
To evaluate the bioequivalence of two venlafaxine formulations, a standard 2-way randomized cross-over study was conducted in twenty-four healthy male Korean volunteers. A single oral dose of 75 mg of test formulation Venfaxine $OR^{(R)}$ (tablet) or reference formulation Efexor $XR^{(R)}$ (capsule) was administered with one-week washout period. Plasma concentrations of venlafaxine were assayed for over a period of 72 hours with a well validated method using liquid chromatography coupled to tandem mass spectrometry (LC-MS-MS). The $mean{\pm}S.D$. of maximum concentration $(C_{max})$ and elimination half-life $(t_{1/2})$ were $64.7{\pm}28.5$ ng/mL, $9.2{\pm}3.0$ h, and $67.2{\pm}30.2$ ng/mL, $9.9{\pm}3.5$ h for test and reference formulations, respectively. Time to reach maximum concentration $(T_{max})$ expressed in median value (range), for the test and the reference, were 10 h (6-14) and 8h (4-12), respectively. Similarly, area under the plasma concentration-time curve, from time zero to last sampling time $(AUC_t)$ and from time zero to time infinity $(AUC_{inf})$, for test and reference formulations were $1185{\pm}755$, $1326{\pm}896$ and $1124{\pm}737$, $1185{\pm}755$ $ng{\cdot}h/mL$, respectively. The parametric 90% confidence intervals on the mean of the differences between the two formulations (test-reference) of the log transformed values of $AUC_t$, and $C_{max}$ were 0.9630 to 1.1383 and 0.8650 to 1.0446, respectively. The overall results indicate that the two formulations are bioequivalent and can be prescribe interchangeably.
제스트릴<sup>®</sup>정(리시노프릴, 10 mg)에 대한 리시헥살<sup>®</sup>정의 생물학적동등성
오수연,디펜드라 쿠마 아리얼,조종태,김형건,김윤균,Oh, Soo-Yeon,Aryal Dipendra Kumar,Cho, Jong-Tae,Kim, Hyung-Gun,Kim, Yoon-Gyoon 한국약제학회 2006 Journal of Pharmaceutical Investigation Vol.36 No.4
Lisinopril is one of the angiotensin-converting enzyme inhibitors, which have been used for treatment of hypertension and heart failure. The aim of this study was to evaluate the bioequivalence of two lisinopril tablet, $Lisihexal^{\circledR}$ and $Zestril^{\circledR}$ as a test and reference, respectively. The study was came out on 28 healthy male Korean volunteers in $2{\times}2$ crossover design. An analytical method with LC-MS-MS was developed for the quantification of lisinopril and enalapril(IS) using SPE method. The condition was selective, sensitive and precise in human plasma, that was enough for the pharmacokinetic study of lisinopril. The pharmacokinetic parameters such as $AUC_t,\;AUC_{inf},\;C_{max},\;T_{max}\;and\;t_{1/2}$ were calculated and ANOVA test was used for the statistical analysis of the parameters using log transformed $AUC_t,\;AUC_{inf}\;and\;C_{max}$. $t_{1/2}$ of test and reference drugs were calculated $11.4{\pm}5.1\;and\;16.1{\pm}9.9\;hr$, respectively. The 90% confidence intervals of $AUC_t,\;AUC_{inf}\;and\;C_{max}$ were log 0.9245$\sim$log 1.0603, log 0.9270$\sim$log 1.0601 and log 0.9548$\sim$log 1.1009, within the acceptable range of log 0.8 to log 1.25 by KFDA bioequivalence criteria. Two medications of lisinopril were evaluated bioequivalent and thus may be prescribed interchangeably.
김근호(Gheun Ho Kim),조종태(Jong Tae Cho),양원석(Won Suk Yang),김윤구(Yoon Goo Kim),한진석(Jin Suk Han),김성권(Suhng Gwon Kim),이정상(Jung Sang Lee) 대한내과학회 1991 대한내과학회지 Vol.40 No.1
N/A In order to observe the sequential changes of the urine electrolytes and urine anion gap (UAG) during the course of Korean hemorrhagic fever (KHF), we measured spot urine electrolytes and urine osmolality in 16 patients with KHF, and calculated UAG from them as an index of the renal tubular dysfunction. Also, we observed the relationships between the initial value of spot urine anion gap and the clinical findings and severity in each patient. Spot urine sodium and potassium concentrations were higher in the early phases (oliguric to early diuretic phase) than in the late phases. Spot UAG values were highest in the oliguric phase and decreased sequentially. Urine osmolality decreased sequentially from the oliguric to the convalescent phase. The initial spot UAC values of each patient were related with the clinical severity in the early phases and with the degrees of hyponatremia, azotemia and metabolic acidosis as well. Spot UAG was elevated when spot urine sodium or potassium concentration was higher, and was lowered when urine osmolality was decreased or polyuria occurred. From the above results, we concluded that the changes of spot UAG through the phases might be related with the renal tubular damage in KHF.